$STEK Balance Sheet | Understand Stock

$STEK

$0.00 +$0.00 (0.0%) Close

$STEK Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of May 31, 2021
Prepaid expenses
Cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other current assets
TOTAL CURRENT ASSETS
Less: accumulated depreciation
Property and equipment, net
Intangible assets, net
Other long term assets
Long term deposits
Total other assets
Operating lease right-of-use assets - net
Goodwill
Intercompany
TOTAL ASSETS
CURRENT LIABILITIES:
Accounts payable and accrued expenses
Notes and accrued interest payable - Note 4
Convertible notes and accrued interest payable - Note 5
Accrued payroll
Accrued liabilities
Notes payable
Common stock payable
Convertible debt current
Notes payable--related parties
Operating lease liabilities - current
Deferred revenues
Factoring liability
Other liabilities
Factoring liability
Derivative liability

TOTAL CURRENT LIABILITIES
Notes payable - Long term
Derivative liabilities - long term
Operating lease liabilities - noncurrent
Total non-current liabilities
Other long term liabilities
TOTAL LIABILITIES
COMMITMENTS AND CONTINGENCIES (Note 12)
Common stock - $0.001 par value; 5,000,000,000 shares authorized; 2,738,521,585 and 425,980,711 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Additional paid in capital
Accumulated other comprehensive loss
Accumulated deficit
Stemtech Corporation shareholders’ deficit
Non-controlling interest in subsidiaries
Net loss
TOTAL STOCKHOLDERS EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

Comments